Superworth

ADC Therapeutics SA EPS ADCT

Diluted earnings per share by quarter and over the last twelve months, from 2023.

Last 12 months, to Jun 30, 2026
−$0.66
Latest quarter, Q2 FY26
−$0.11
Fiscal year 2025
−$1.20

ADC Therapeutics SA's earnings per share was −$0.66 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.11.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.20n/a
FY2024−$1.65n/a
FY2023−$2.93n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.11n/a−$0.66
Q1 FY26−$0.21n/a−$1.05
Q4 FY25−$0.04n/a−$1.20
Q3 FY25−$0.30n/a−$1.45
Q2 FY25−$0.50n/a−$1.57
Q1 FY25−$0.36n/a−$1.45
Q4 FY24−$0.29n/a−$1.65
Q3 FY24−$0.42n/a−$2.39
Q2 FY24−$0.38n/a−$2.54
Q1 FY24−$0.56n/a−$2.76
Q4 FY23−$1.03n/a−$2.93
Q3 FY23−$0.57n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest ADC Therapeutics SA's size, closest first, today.

CompanyEPS, 12 monthsGrowth
ADCTADC Therapeutics SA−$0.66
NATRNatures Sunshine Products$1.01+36% a year
LFVNLifevantage$0.40−46% a year
ARVNArvinas$0.16
SPROSpero Therapeutics$0.11
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
ATNMActinium Pharmaceuticals$0.36
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on ADC Therapeutics SA

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.